A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 439 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Resource Round-Up: Let’s Win Pancreatic Cancer May 23, 2023 FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab... August 5, 2026 BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 Cómo puede ayudar la terapia del piso pélvico a las personas... December 13, 2022 Load more HOT NEWS Best Friends and Owners of a Specialty Cheese Shop Battle Breast... EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... Can Having Solar Panels or Living Near a Solar Farm Increase... EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib
